The Liposome Company Evacet
Executive Summary
Additional clinical data will be needed to gain FDA approval for metastatic breast cancer based on discussions with FDA, company says Feb. 3. The company is considering foregoing the metastatic indication in favor of pursuing a lymphoma indication. The company had submitted analyses to FDA to support resubmission of the Evacet application following withdrawal of the original application (1"The Pink Sheet" Oct. 18, 1999, In Brief)